Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (7,433,608)	$ (6,851,689)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	0	0
Change in fair value of warrant liabilities	(456,177)	(11,126)
Stock-based compensation expense	369,075	51,527
Changes in operating assets and liabilities:
Prepaid clinical trial costs	(701,307)	(26,035)
Prepaid expenses and other current assets	(488,744)	(1,216,117)
Accounts payable	1,871,347	(659,693)
Accrued expenses and other current liabilities	(4,886,395)	761,736
Net cash used in operating activities	(11,725,809)	(7,951,397)
Cash flows from financing activities
Proceeds from issuance of short-term debt	415,000	667,500
Repayment of short-term debt	(83,000)	0
Proceeds from exercise of warrants	0	19,593
Net cash provided by financing activities	332,000	687,093
Net decrease in cash and cash equivalents	(11,393,809)	(7,264,304)
Cash and cash equivalents, beginning of period	23,367,456	18,519,856
Cash and cash equivalents, end of period	11,973,647	11,255,552
Supplemental disclosures of cash flow information:
Cash paid for taxes	657	2,241
Cash paid for interest	$ 3,487	$ 0